No Data
No Data
Eli Lilly Set To Report Earnings As Investors Eye Weight Loss Drug Momentum
WeightWatchers Rises on Partnership With Eli Lilly to Enhance Zepbound Access
Nvidia, Johnson & Johnson, Hyundai, Toyota, SoftBank CEOs To Join Trump At White House As He Touts Investment Surge In First 100 Days: Report
Goldman Sachs: Oral weight loss drugs will be one of the most promising new medications in recent years!
Goldman Sachs predicts that by 2030, oral weight loss drugs will account for 24% of the total weight loss drug market, and Eli Lilly and Co will lead this segment with its orforglipron. Next, pay close attention to the third-quarter results of the ATTAIN-1 trial announced by Eli Lilly, which will be the first reading of orforglipron in the field of obesity and the most important next catalyst for the oral obesity drug market.
Plaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications
AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst